Wird geladen...
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3‐Mutated AML
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients....
Gespeichert in:
| Veröffentlicht in: | Oncologist |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley & Sons, Inc.
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869119/ https://ncbi.nlm.nih.gov/pubmed/33368797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13652 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|